Institute of Internal Medicine, G. Rodolico, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Università di Catania, Italy.
Drug Discov Today. 2012 Jun;17(11-12):591-9. doi: 10.1016/j.drudis.2012.01.012. Epub 2012 Jan 25.
Patients with severe asthma suffer persistent symptoms and/or frequent exacerbations despite high-intensity treatment. Their severe unrelenting symptoms have a huge impact on healthcare resources owing to frequent hospital admissions and requirement for intensive treatments. Consequently, there is an undeniable need for more-effective and safer medications. Expanding knowledge of innate and adaptive immune responses is leading to the development of novel therapies for severe asthma. Herein, we review efficacy and safety data from human clinical trials of monoclonal antibodies that are approved or under investigation for use in asthma. Future drug candidates directed at key targets and the specific role of monoclonal antibodies in distinctively targeted sub-populations of severe asthmatics will be also discussed.
尽管接受了高强度治疗，重度哮喘患者仍会持续出现症状和/或频繁恶化。由于频繁住院和需要强化治疗，他们严重且持续的症状对医疗资源造成了巨大影响。因此，确实需要更有效和更安全的药物。对先天和适应性免疫反应的深入了解，推动了新型哮喘治疗药物的研发。本文综述了已获批或正在临床试验阶段的用于哮喘治疗的单克隆抗体的疗效和安全性数据。文中还讨论了针对关键靶点的候选药物和单克隆抗体在特定重度哮喘亚群中的具体作用。
